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PLATELETS AND THROMBOPOIESIS
Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization,
secondary mediators, and Rac
Alice Y. Pollitt,1 Beata Grygielska,1 Bertrand Leblond,2 Laurent De´sire´,2 Johannes A. Eble,3 and Steve P. Watson1
1Centre for Cardiovascular Sciences, Institute for Biomedical Research, The College of Medical and Dental Sciences, University of Birmingham, Birmingham,
United Kingdom; 2ExonHit Therapeutics, Paris, France; and 3Center for Molecular Medicine, Excellence Cluster Cardio-Pulmonary System, Frankfurt University
Hospital, Frankfurt am Main, Germany
The C-type lectin-like receptor 2 (CLEC-2)
activates platelets through Src and Syk
tyrosine kinases via a single cytoplasmic
YxxL motif known as a hem immunorecep-
tor tyrosine-based activation motif (hemI-
TAM). Here, we demonstrate using su-
crose gradient ultracentrifugation and
methyl--cyclodextrin treatment that
CLEC-2 translocates to lipid rafts upon
ligand engagement and that transloca-
tion is essential for hemITAM phosphory-
lation and signal initiation. HemITAM
phosphorylation, but not translocation, is
also critically dependent on actin polymer-
ization, Rac1 activation, and release of
ADP and thromboxane A2 (TxA2). The role
of ADP and TxA2 in mediating phosphory-
lation is dependent on ligand engage-
ment and rac activation but is indepen-
dent of platelet aggregation. In contrast,
tyrosine phosphorylation of the GPVI-
FcR-chain ITAM, which has 2 YxxL mo-
tifs, is independent of actin polymeriza-
tion and secondary mediators. These
results reveal a unique series of proximal
events in CLEC-2 phosphorylation involv-
ing actin polymerization, secondary me-
diators, and Rac activation. (Blood. 2010;
115(14):2938-2946)
Introduction
Dectin-1, C-type lectin-like receptor 2 (CLEC-2), and CLEC-9A
are C-type lectin receptors which have been shown to sig-
nal through an immunoreceptor tyrosine-based activation motif
(ITAM)–like pathway via a single YxxL in their short cytoplasmic tails
known as a hemITAM.1-4 Tyrosine phosphorylation of the conserved
tyrosine and both SH2 domains of the tyrosine kinase Syk have been
shown to be essential for activation of Syk by CLEC-2 and dectin-1,
favoring a model in which the tyrosine kinase is activated by the
cross-linking of 2 receptors.2 This is consistent with the observations
that CLEC-9A is a disulphide-linked dimer and that CLEC-2 is
expressed as a noncovalent dimer.1,5
CLEC-2 is highly expressed in platelets and at lower levels in
other hematopoietic cells, including neutrophils and dendritic
cells.6,7 It is a type II transmembrane protein and a nonclassical
C-type lectin that lacks the conserved amino acids that mediate
binding to glycans.7 CLEC-2 was identified by affinity chromatog-
raphy as a ligand for the snake venom protein rhodocytin, purified
from the Malayan pit viper, Calloselasma rhodostoma.3 Indepen-
dent crystal structures of rhodocytin show that it assembles as a
tetramer, which leads to the suggestion that it mediates activation
of CLEC-2 through clustering.8,9 Consistent with this clustering
model of activation, whole antibodies and F(ab)2 fragments have
been reported to activate CLEC-2, whereas antibody Fab fragments
were inhibitory.3,10,11
Physiologic roles of CLEC-2 are now beginning to emerge.
Recently, CLEC-2 has been implicated in tumor metastasis via its
interaction with the type I sialoglycoprotein podoplanin, which is
also expressed on the surface of kidney podocytes, lung type I
alveolar cells, and lymphatic endothelium.12-14 CLEC-2 has also
been shown to play a role in neutrophil phagocytosis.15 Evidence
obtained using antibody depletion of CLEC-2 from mouse platelets
has shown that it plays an important role in hemostasis and
thrombosis at arteriolar rates of flow.11
Studies on platelets and mutant cell lines have demonstrated
that CLEC-2 and the other hemITAM receptors share many of the
signaling features of receptors that signal via ITAMs. The ITAM
motif is defined by the sequence YxxLx6-12YxxL, and is found in
receptors such as the T-cell receptor and the platelet collagen
receptor, GPVI-FcR-chain.16 The characteristic ITAM signaling
features include sequential activation of Src and Syk family
kinases, adapter proteins such as LAT, SLP-76, and BLNK, and
activation of PLC2.2,3,17 Nevertheless, we have demonstrated that
the proximal events in the CLEC-2 signaling cascade are distinct
from that for ITAM receptors in that phosphorylation of the
hemITAM is mediated by both Src and Syk tyrosine kinases,
whereas phosphorylation of the ITAM is mediated solely by Src
kinases.10
ITAM receptors signal through cholesterol-rich lipid membrane
domains, known as lipid rafts or GEMS.18-20 These specialized
regions of the membrane are enriched in many signaling proteins,
including Src family kinases and the membrane adapter protein
LAT.21 In addition, the cytoskeleton plays a contributory, but
poorly understood role in signaling by ITAM receptors.22 Recently,
dectin-1 has also been shown to signal in lipid rafts,23 but it is not
known if this is also the case for CLEC-2.
The aim of the present study was to investigate the role of lipid
rafts and the actin cytoskeleton in platelet activation by CLEC-2
alongside that of GPVI to investigate whether this could explain the
differential reliance of the 2 receptors on Src and Syk kinases in
mediating hemITAM and ITAM phosphorylation.
Submitted December 3, 2009; accepted January 12, 2010. Prepublished online
as Blood First Edition paper, February 12, 2010; DOI 10.1182/blood-2009-12-
257212.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2010 by The American Society of Hematology
2938 BLOOD, 8 APRIL 2010  VOLUME 115, NUMBER 14
Methods
Reagents
Rhodocytin was purified from C rhodostoma venom as previously de-
scribed.24 Antibodies used included goat anti–human CLEC-2 antibody
(R&D Systems), mouse antiphosphotyrosine antibody (4G10; Upstate
Biotechnology, TCS Biologicals Ltd), mouse anti-Rac antibody, 23A8
(Upstate Biotechnology), rabbit anti-PLC2, and rabbit anti-Syk polyclonal
antibodies were from previously described sources.25 Mouse anti-integrin
IIb-specific antibody SZ22 was from Immunotech, rabbit anti-LAT anti-
body was from Upstate Biotechnology, and rat anti-podoplanin antibody
NZ-1 was from AngioBio. Horseradish peroxidase (HRP)–conjugated
anti–mouse and anti–rabbit IgGs were obtained from GE Healthcare, and
HRP-conjugated anti–rat IgG was obtained from Santa Cruz Biotechnol-
ogy. EHT 1864 was obtained from ExonHit Therapeutics, and Cangrelor, a
P2Y12 inhibitor, was obtained from The Medicines Company. Eptifibatide
was obtained from the University Hospital Birmingham’s pharmacy. All
other reagents were purchased from Sigma-Aldrich.
Preparation of human platelets
Venous blood from healthy drug-free volunteers was taken into 10%
sodium citrate, and washed platelets were prepared as previously de-
scribed.2 They were resuspended in a modified HEPES Tyrode buffer
(composition: 134mM NaCl, 2.9mM KCl, 0.34mM Na2PO4.12H2O, 12mM
NaHCO3, 20mM HEPES, 1mM MgCl2, and 5mM glucose [pH 7.3]).
Platelet aggregation
Aggregation was monitored by light transmission using a Born lumi-
aggregometer (Chronolog).
MCD treatment
For cholesterol depletion, washed platelets were incubated with 5mM,
2.5mM, or 1mM methyl--cyclodextrin (MCD) for 1 hour at room
temperature before stimulation.
Lipid raft isolation
For membrane preparation, cells (0.5 mL at 1.5  109 platelets/mL) were
disrupted in ice-cold lysis buffer (25mM Tris-HCL [pH 7.6], 150mM NaCl,
5mM EDTA, 1% Brij 58, 1mM phenylmethylsulfonyl fluoride [PMSF],
2mM sodium orthovanadate [Na3VO4], 10 g/mL leupeptin, 10 g/mL
aprotinin, and 1 g/mL pepstatin A). The same buffer was used for the
sucrose gradient solutions. The lysate was mixed with an equal volume of
80% (wt/vol) sucrose, producing a final concentration of 40%. The lysate
was loaded on the bottom of an ultracentrifuge tube and overlaid with 2 mL
of 30% (wt/vol) sucrose followed by 1 mL of 5% (wt/vol) sucrose. Lipid
rafts were separated from nonraft and cytoskeleton components by ultracen-
trifugation (48 000g for 16 hours). After fraction isolation, 1% (wt/vol)
N-dodecyl--D-gluco-maltoside was added to solubilize the lipid rafts.
Fractions were analyzed by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE).
Immunoprecipitation studies
Washed resting or stimulated platelets (1.5  108), pretreated with 9M
eptifibatide to inhibit platelet activation and aggregation through integrin
IIb3, were lysed with an equal volume of 2  lysis buffer (20mM
Tris/HCL [pH 7.5], 300mM NaCl, 2mM EGTA, 2mM EDTA, 2% NP-40,
2mM PMSF, 5mM Na3VO4, 10 g/mL leupeptin, 10 g/mL aprotinin, and
1 g/mL pepstatin). Cell debris was removed by centrifugation (15 000g
for 10 minutes). After preclearing, proteins were captured by antibodies
bound to either protein G–sepharose or protein A–sepharose. Samples were
separated on a SDS-PAGE along side a molecular weight marker and
transferred onto a polyvinylidene difluoride (PVDF) membrane. After
blocking, the membranes were incubated with primary antibody overnight,
washed, and then incubated with HRP-conjugated secondary antibody for
1 hour. Immunoprecipitated proteins were visualized by chemilumines-
cence (ECL; Pierce).
Rac pull-down assay
Eptifibatide-treated platelets were lysed with 2 lysis buffer (100mM
Tris-HCL [pH 7.5], 1M NaCl, 20mM MgCl2, 1% deoxycholate, 0.2% SDS,
2% Triton X-100, 2mM PMSF, 10 g/mL leupeptin, 20 g/mL aprotinin,
and 5mM EGTA). Lysates were centrifuged at 18 000g at 4°C for
10 minutes. Equal volumes of lysates were incubated with glutathione-S-
transferase–PAK bound to glutathione-sepharose beads for 30 minutes at
4°C. The beads were washed 3 times with wash buffer (50mM Tris-HCL
[pH 7.5], 150mM NaCl, 10mM MgCl2, 1% Triton X-100, 1mM PMSF,
10 g/mL leupeptin, 5 g/mL aprotinin, and 5mM EGTA). The Rac1
proteins bound to the beads were detected by Western blotting using
anti-Rac1 antibodies.
Generation of podoplanin-expressing CHO cells
Chinese Hamster Ovary (CHO) cells were transfected with pcDNA3
containing full-length human podoplanin using a calcium phosphate
transfection method. Stable transfectants were obtained using media
containing 1 mg/mL geneticin (G418) and clonal cell populations obtained
after serial dilutions into 96-well plates. Surface expression of human
podoplanin was assessed by flow cytometry.
Results
CLEC-2 localizes to lipid rafts upon stimulation with rhodocytin
Lipid rafts are plasma microdomains which have been shown to
play an important role in signaling by ITAM receptors. To assess
the role of these specialized membrane regions in signaling by
CLEC-2, we measured the presence of CLEC-2 in lipid rafts under
resting and stimulated conditions. Brij 58 has previously been
shown to preserve lipid rafts over a wide range of concentrations
and was selected as the detergent of choice in this study.26 Brij
58-solubilized platelet lysates were separated into lipid raft frac-
tions and nonraft fractions by sucrose gradient ultracentrifugation
and analyzed by SDS-PAGE. The presence of CLEC-2, which runs
as a doublet due to differential glycosylation,3 was investigated by
Western blotting using a specific antibody. In control, nonstimu-
lated platelets, approximately 5% of CLEC-2 was found in the
detergent-insoluble fraction (Figure 1A-B). The detergent-
insoluble fraction was enriched in the lipid raft marker protein LAT
but excluded the nonraft marker, the integrin IIb subunit.26
Stimulation of platelets by rhodocytin caused an approximate 35%
redistribution of CLEC-2 to the detergent-insoluble fraction (Fig-
ure 1A-B) raising the possibility that it signals through these
lipid-rich membrane domains. To investigate this further, we
monitored tyrosine phosphorylation of CLEC-2 after immunopre-
cipitation from lipid raft and nonraft fractions of rhodocytin-
stimulated platelets (Figure 1C). Approximately 90% of tyrosine-
phosphorylated CLEC-2 was found within the insoluble, lipid raft
membrane domain consistent with a model in which signaling by
the lectin receptor takes place in the cholesterol-rich membrane
domains.
As CLEC-2 phosphorylation by Src and Syk family kinases is
critical for platelet activation, we investigated whether movement
of CLEC-2 to the lipid raft fraction was blocked by pretreatment of
platelets with the Src kinase inhibitor PP2. Incubation of platelets
with PP2 completely inhibits tyrosine phosphorylation of CLEC-2
(data not shown), in confirmation of previous publications,3,10 but
MECHANISM OF CLEC-2 PHOSPHORYLATION 2939BLOOD, 8 APRIL 2010  VOLUME 115, NUMBER 14
had no effect on its movement to the lipid raft fraction (supplemen-
tal Figure 1, available on the Blood website; see the Supplemental
Materials link at the top of the online article), demonstrating that
translocation occurs before tyrosine phosphorylation.
The cholesterol-lowering agent MCD was used to further
investigate the role of lipid rafts in rhodocytin signaling. In
agreement with previous reports,27,28 we found that pretreatment of
platelets with a relatively high concentration (5mM) of MCD
caused mild ( 20%) inhibition of thrombin induced aggregation,
whereas there was no effect at lower MCD concentrations (Figure
2A). In contrast, MCD caused a marked, concentration-dependent
inhibition of rhodocytin-induced aggregation that reduced the
response by greater than 95% at 5mM, with a partial effect
observed at lower concentrations (1-2mM). Consistent with this,
both whole-cell tyrosine phosphorylation and CLEC-2 tyrosine
phosphorylation by rhodocytin were inhibited by MCD in a
concentration-dependent manner (data not shown; Figure 2B).
Together, these data demonstrate a critical role for lipid rafts in
signaling by the snake venom toxin and support a model in which
translocation to the raft fractions occurs before phosphorylation of
the hemITAM receptor.
Cytochalasin D inhibits rhodocytin signaling
The actin cytoskeleton plays a contributory but poorly defined
role in signaling by ITAM receptors. We therefore used cytocha-
lasin D, a powerful inhibitor of actin polymerization, to
investigate the role of actin polymerization in the movement of
CLEC-2 to lipid rafts and platelet activation by rhodocytin.
Figure 1. CLEC-2 translocates to lipid rafts upon stimulation.
(A) Resting and rhodocytin-stimulated platelets were lysed in the
presence of 1% Brij 58 and separated into lipid raft and nonraft
fractions by sucrose gradient ultracentrifugation. The localization
of CLEC-2 was determined by immunoblotting with specific
antibodies. The lipid raft fractions were identified using an anti-
LAT blot, and nonraft fractions were identified using an anti–
integrin IIb blot. (B) Characterization of fractions from basal and
rhodocytin stimulated platelets pretreated with DMSO or 10M
cytochalasin D. Data represent the mean and standard error of
3 independent experiments. (C) CLEC-2 was immunoprecipitated
from lipid raft and nonraft fractions of platelets stimulated with
100nM rhodocytin and blotted with an antiphosphotyrosine anti-
body. Membranes were subsequently stripped and reblotted with
anti–CLEC-2. Data are representative of at least 3 independent
experiments.
Figure 2. Lipid raft disruption by MCD impairs
CLEC-2 signaling. (A) Platelets were pretreated with
indicated concentrations of MCD and stimulated with
30nM rhodocytin or 0.1 U/mL thrombin. (Left) Represen-
tative aggregation traces are shown for control and
MCD-treated platelets. Addition of agonist is indicated
by an arrowhead. The aggregation traces have been
staggered. (Right) The percentage of transmittance of
platelets pretreated with decreasing concentrations of
MCD-treated platelets stimulated with rhodocytin or
thrombin was measured after 5 minutes. Data represent
the mean and standard error of 3 independent experi-
ments. (B) CLEC-2 was immunoprecipitated from plate-
lets pretreated with indicated concentrations of MCD
and stimulated with vehicle or 30nM rhodocytin and
blotted with an antiphosphotyrosine antibody. Mem-
branes were subsequently stripped and reblotted with
anti–CLEC-2. Data are representative of 3 indepen-
dent experiments.
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Cytochalasin D (10M) had no effect on the translocation of
CLEC-2 to lipid rafts (Figure 1B; supplemental Figure 1), but
completely abrogated tyrosine phosphorylation of the lectin
receptor, demonstrating a pivotal role for actin polymerization
in the early events underlying receptor signaling. Consistent
with this, whole-cell tyrosine phosphorylation, including ty-
rosine phosphorylation of Syk and PLC2, were completely
inhibited in the presence of a maximally effective (10M)
concentration of cytochalasin D (Figure 3A-B). Furthermore,
cytochalasin D (10M) blocked aggregation to low concentra-
tions of rhodocytin and inhibited the response to higher
concentrations of the snake venom by more than 70%, while a
submaximal concentration of cytochalasin D (1M) caused a
marked increase in the lag phase that precedes aggregation
(Figure 3C-D). In contrast, a maximal concentration of cytocha-
lasin D (10M) had no significant effect on tyrosine phosphory-
lation of Syk and PLC2 induced by the GPVI-specific agonists
collagen-related peptide (CRP) and convulxin (Figure 3A-B),
and caused only a marginal decrease in the rate of late-stage
aggregation with no effect on the maximal response (Figure
3C-D). Comparable observations for both rhodocytin- and
GPVI-mediated responses were seen with a second inhibitor of
actin polymerization, latrunculin A (data not shown). These
results therefore demonstrate a critical role for actin polymeriza-
tion in platelet activation by rhodocytin.
Role of secondary mediators in rhodocytin signaling
The secondary mediators ADP and TxA2 play a critical positive
feedback role in mediating platelet activation by all agonists,
although for many their action is obviated at high agonist concen-
trations.29 To investigate the dependency on secondary mediators
Figure 3. Platelet responses to rhodocytin are impaired upon cytochalasin D treatment. (A) Whole-cell lysates from basal or agonist-stimulated platelets preincubated
with various doses of cytochalasin D were separated by SDS-PAGE, and tyrosine phosphorylation was assessed using an antiphosphotyrosine antibody. (B) Whole-cell lysates
were isolated from resting or platelets stimulated with (i) rhodocytin, (ii) CRP, or (iii) convulxin, treated with or without cytochalasin D. CLEC-2, PLC2, and Syk were
immunoprecipitated and the samples separated by SDS-PAGE and immunoblotted for CLEC-2, PLC2, and Syk. Their tyrosine-phosphorylated states were assessed using
an antiphosphotyrosine antibody. (C) Platelets pretreated with various concentrations of cytochalasin D were stimulated with (i) 30nM rhodocytin, (ii) 3 g/mL CRP, and
(iii) 1 g/mL convulxin. Addition of agonist is indicated by an arrowhead. Representative aggregation traces are shown for control and cytochalasin D–treated platelets.
(D) Dose responses to (i) rhodocytin, (ii) CRP, and (iii) convulxin. Platelets pretreated with DMSO or 10M cytochalasin D are shown as mean and standard error of 3 independent
experiments.
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for platelet activation by rhodocytin, we used the ADP scavenger,
apyrase, and the cyclooxygenase inhibitor, indomethacin. Strik-
ingly, the combination of apyrase and indomethacin abolished
platelet aggregation to a 30-nM concentration of rhodocytin
(Figure 4Ai). The inhibition seen in the presence of secondary
mediators could not be overcome with higher concentrations of
rhodocytin (Figure 4Aii). Strikingly, however, the movement of
CLEC-2 into lipid rafts induced by rhodocytin was not altered in
the presence of the 2 inhibitors (supplemental Figure 1). The
increase in whole-cell tyrosine phosphorylation induced by rhodo-
cytin (100nM) and phosphorylation of CLEC-2 was also dramati-
cally reduced in the presence of apyrase and indomethacin (Figure
4B; data not shown). The residual increase in tyrosine phosphoryla-
tion induced by rhodocytin in the presence of apyrase and
indomethacin was inhibited in the presence of PP2 or cytochalasin
D (Figure 4B).
As the presence of secondary mediators lead to a substantial
amplification in CLEC-2 tyrosine phosphorylation we assessed the
effect of ADP and a TxA2 mimetic (U46619) on CLEC-2 phosphor-
ylation. ADP and U46619 had no significant effect on CLEC-2
phosphorylation (Figure 4C). Thus, the role of secondary mediators
in regulating CLEC-2 tyrosine phosphorylation and downstream
signaling is indirect. We further assessed the effect ADP and
U46619 had on rhodocytin-mediated CLEC-2 phosphorylation
after inhibition of actin polymerization. We found that the 2 second-
ary mediators were able to partially restore phosphorylation of
CLEC-2 in the presence of cytochalasin D (Figure 4E) demonstrat-
ing that actin polymerization lies upstream of secondary mediator
generation and further CLEC-2 phosphorylation.
Further studies were designed to investigate whether the effect
of apyrase and indomethacin was due to blockade of the P2Y1,
P2Y12, or TxA2 receptors, or a combination of these effects (Figure
4Aiii,D). The antagonists MRS2179 and Cangrelor are selective to
P2Y1 and P2Y12 receptors, respectively, and indomethacin prevents
the formation of TxA2 by blocking cyclooxygenase. Inhibition of
the P2Y1 receptor had no effect on rhodocytin-induced platelet
aggregation or CLEC-2 phosphorylation. Inhibition of the P2Y12
receptor caused a slight inhibition in rhodocytin-induced aggrega-
tion and CLEC-2 phosphorylation. In contrast, the greatest inhibi-
tion in rhodocytin-induced aggregation was seen when TxA2
formation was inhibited. This also resulted in a near loss in
CLEC-2 phosphorylation. These data suggest that the major
feedback mechanism that leads to an increase in CLEC-2 phosphor-
ylation is downstream of the TxA2 receptor, but that there is limited
synergy with signaling downstream of the P2Y12 and P2Y1
receptors, as a combination of apyrase and indomethacin further
reduces CLEC-2 phosphorylation.
Figure 4. Role of secondary mediators in rhodocytin induced aggregation and protein phosphorylation. (Ai,iii) Platelets pretreated with or without inhibitors were
stimulated with 30nM rhodocytin. Addition of agonist is indicated by an arrowhead. (ii) Dose responses to rhodocytin. Platelets pretreated with vehicle or 2 U/mL apyrase/10M
indomethacin are shown as mean and standard error of 3 independent experiments. Protein phosphorylation measurements (B-E) were performed in the presence of
eptifibatide to prevent platelet aggregation. (B) Whole-cell lysates were prepared from control and rhodocytin-stimulated platelets with or without secondary mediators and
indicated inhibitors. (C) CLEC-2 was immunoprecipitated from basal-, U46619/ADP-, and rhodocytin-stimulated platelet lysates, and tyrosine phosphorylation was assessed.
(D) CLEC-2 was immunoprecipitated from rhodocytin-stimulated platelets pretreated with inhibitors, and tyrosine phosphorylation was assessed. (E) CLEC-2 was
immunoprecipitated from rhodocytin-stimulated platelets pretreated with the indicated inhibitors with or without the addition of ADP/U46619, and tyrosine phosphorylation was
assessed. Data shown are representative of 3 independent experiments.
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CLEC-2 phosphorylation requires Rac1
Studies on platelets from Rac1-deficient mice have shown that
Rac1, a member of the Rho family of small GTPases, plays a
critical role in mediating PLC2 activation by GPVI in platelets
leading to inhibition of Ca2 mobilization.30,31 Consistent with this,
we observed concentration-dependent inhibition of Rac activation
and aggregation of human platelets in response to CRP in the
presence of the novel and selective Rac1 inhibitor, EHT 186432
(Figure 5Ai-ii). This demonstrates that Rac1 also plays a similar
role in GPVI signaling in human platelets.
To investigate a possible role of Rac1 in rhodocytin-signaling in
human platelets, we first monitored Rac activation using a GST-
PAK1–binding assay that selectively precipitates GTP-bound Rac.31
Formation of GTP-bound Rac after stimulation by rhodocytin was
detected at 30 seconds and peaked at 45 seconds before declining
to a plateau (Figure 5B). The delay in activation corresponds to the
characteristic lag seen for rhodocytin-induced platelet aggregation
(data not shown). Activation of Rac1 by rhodocytin was inhibited
in the presence of cytochalasin D and apyrase/indomethacin,
suggesting that it may lie downstream of actin polymerization or
second messenger generation (data not shown).
The Rac1 inhibitor, EHT 1864, completely inhibited formation
of GTP-bound Rac1 by rhodocytin at 50M and caused partial
inhibition at 10M (Figure 5C), with a similar concentration-
response relationship for inhibition of aggregation (Figure 5Di).
EHT 1864 also markedly inhibited whole-cell tyrosine phosphory-
lation (data not shown) and phosphorylation of CLEC-2 (Figure
5Dii) over the same concentration range. The residual increase in
whole-cell tyrosine phosphorylation observed in the presence of
EHT 1864 was retained in the presence of apyrase and indometha-
cin (Figure 4B). On the other hand, the inhibition of phosphoryla-
tion of CLEC-2 by rhodocytin in the presence of EHT 1864
was only weakly restored in the presence of U46619 and ADP
(Figure 4E). These results therefore support a model in which
rhodocytin stimulates weak tyrosine phosphorylation of CLEC-2
and whole-cell phosphorylation independent of Rac1, but that
activation of the GTPase, most likely by ADP and TxA2, is required
for robust tyrosine phosphorylation of CLEC-2 and whole-cell
phosphorylation.
Podplanin-induced aggregation signals in a similar way to
rhodocytin
Podoplanin-expressing but not mock-transfected CHO cells have
previously been shown to induce platelet aggregation.13 CHO cells
that stably express human podoplanin (hPodoCHO) were gener-
ated, and surface expression of human podoplanin was assessed by
flow cytometry (Figure 6A). The addition of hPodoCHO cells to
platelets induces a similar pattern of aggregation to that seen with
rhodocytin in that it is preceded by a characteristic lag phase
(Figure 6B). Pretreatment of platelets with the lipid raft–disrupting
agent MCD, the actin-disrupting drug cytochalasin D, inhibitors
of secondary mediators, or the Rac inhibitor EHT1864 all inhibited
platelet aggregation in response to hPodoCHO. These results
therefore demonstrate a similar profile of platelet activation by the
endogenous ligand podoplanin to that induced by rhodocytin.
Discussion
The present data support a model in which rhodocytin-mediated
platelet activation occurs in membrane rafts through activation of
Src and Syk family kinases and actin polymerization, and is
reinforced by the release of the secondary mediators, ADP and
TxA2, and Rac activation. The following observations form the
basis of the model shown in Figure 7: (1) CLEC-2 translocates to
Figure 5. Role of Rac1 in rhodocytin-induced aggre-
gation and signaling. (Ai) Platelets were pretreated with
indicated amounts of EHT 1864 and platelet aggregation
was measured after addition of 3 g/mL CRP. Addition of
agonist is indicated by an arrowhead. (ii) Lysates were
made from platelets pretreated with indicated amounts of
EHT 1864 stimulated with or without CRP. Active Rac
was pulled-down with a GST-fusion protein containing
the Rac binding domain of PAK1 and detected by
immunoblotting for Rac. (B) Time course of Rac activa-
tion in human platelets stimulated with 100nM rhodocy-
tin. Platelets were stimulated with rhodocytin; at the
indicated times, activation was stopped by the addition of
ice-cold lysis buffer. Active Rac was pulled-down and
detected by immunoblotting for Rac. (C) Lysates were
made from platelets pretreated with indicated amounts of
EHT 1864 and stimulated with or without rhodocytin.
Active Rac was pulled-down and detected by immunoblot-
ting for Rac. (D) Platelets pretreated with decreasing
concentrations of EHT 1864 were stimulated with 300nM
rhodocytin. (i) Aggregation traces are shown for control
and EHT 1864–treated platelets stimulated with 300nM
rhodocytin. (ii) CLEC-2 was immunoprecipitated from
platelets pretreated with indicated concentrations of EHT
1864 and stimulated with vehicle or 30nM rhodocytin and
blotted with an antiphosphotyrosine antibody. Mem-
branes were subsequently stripped and reblotted with
anti–CLEC-2. Data are representative of 3 independent
experiments.
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lipid rafts independently of activation of Src kinases, actin polymer-
ization, and release of ADP and TxA2; (2) tyrosine phosphorylation
of CLEC-2 occurs in lipids rafts; (3) CLEC-2 tyrosine phosphory-
lation is dependent on actin polymerization as demonstrated by
complete inhibition by cytochalasin D; (4) tyrosine phosphoryla-
tion of CLEC-2 and downstream signaling events are reinforced by
the release of secondary mediators, with TxA2 formation playing
the predominant role; (5) the combination of ADP and TxA2
partially restores phosphorylation of CLEC-2; and (6) Rac1
activation, which is presumably mediated downstream of the
secondary mediators, is essential for this feedback phosphorylation
of CLEC-2 to occur.
The involvement of lipid rafts in mediating platelet activation
through CLEC-2 is not surprising given that 6 of the 7 Src family
kinases that have been described in platelets are palmitoylated (Src
is the exception) in their unique N-terminal regions. This targets
them to specialized cholesterol-rich membrane domains, which are
also enriched with many other signaling proteins.33,34 This includes
the membrane adapter LAT, which has previously been shown to
mediate platelet activation by CLEC-2.3,17 Furthermore, signaling
by ITAM receptors in platelets and in other cells is known to occur
in lipid rafts, as illustrated by studies on the platelet ITAM
receptors GPVI and FcRIIA.19,26,35,36 The ITAM-like receptor,
dectin-1, another hemITAM-containing receptor, has also been
shown to be recruited to lipid rafts upon activation.23 Thus, it would
appear that lipid rafts play a critical role in supporting cell
activation by both ITAM- and hemITAM-containing receptors.
It can be speculated that clustering of CLEC-2 by rhodocytin,
which is a tetramer, causes movement into the cholesterol-enriched
membrane domains. The molecular basis of this movement is
unclear, although the present study has shown that this is indepen-
dent of actin polymerization. Within the lipid raft environment,
CLEC-2 becomes phosphorylated through a pathway that is
dependent on actin polymerization, although this can be bypassed
by the addition of ADP and U46619 to mimic secondary mediator
formation. It is this step that contrasts markedly with signaling by
ITAM receptors, as phosphorylation of Syk and PLC2 is not
dependent on actin polymerization. The critical role of actin
polymerization in the proximal events in the CLEC-2 signaling
cascade could be explained by the retention or presentation of key
signaling molecules in the vicinity of the C-type lectin receptor
such as Src or Syk kinases. Actin polymerization, however, does
not appear to be required for dimerization/oligomerization of
CLEC-2 as shown using the cross-linking reagent Sulfo-EGS
(supplemental Figure 2). Further, dimerization/oligomerization of
CLEC-2 is also observed in the presence of apyrase and
indomethacin.
In contrast to the complete inhibition of CLEC-2 tyrosine
phosphorylation seen in the presence of Src kinase or actin
polymerization inhibitors, a residual level of phosphorylation is
seen in the presence of apyrase/indomethacin or Rac1 inhibi-
tion. The ability of ADP and the TxA2 mimetic U46619 to
partially rescue CLEC-2 phosphorylation of platelets treated
with cytochalasin D but not the Rac1 inhibitor EHT1864
supports this hypothesis. This suggests a role for the secondary
mediators and Rac activation in amplification of an initial
receptor signal and is consistent with the ability of ADP and the
TxA2 mimetic U46619 to partially rescue CLEC-2 phosphoryla-
tion of platelets treated with cytochalasin D but not the Rac1
inhibitor EHT1864. The molecular basis of the action of Rac in
supporting signaling by CLEC-2 is unclear, although a number
of possibilities can be put forward. Rac1 has been shown to
support activation of PLC2 through a direct interaction at the
level of the split PH domain in the lipase.37,38 Rac1 also
Figure 6. Signaling via podoplanin displays strong similarities to rhodocytin. (A) The level of surface expression of CHO cells stably expressing human podoplanin
(hPodoCHO) was confirmed by flow cytometry using the anti-podoplanin antibody NZ-1 (infill: CHO cells; overlay: hPodoCHO cells). (B) Human washed platelets (6  108/mL)
pretreated with the indicated inhibitors were stimulated by 4  106/mL hPodoCHO cells, and platelet aggregation was monitored by aggregometry. Data are representative of
3 independent experiments.
Figure 7. Model for CLEC-2 signaling. Our observations support the following
model: (1) CLEC-2 translocates to lipid rafts independently of Src kinases, actin
polymerization and release of ADP and TxA2; (2) Src kinase phosphorylation of
CLEC-2 occurs in lipids rafts; (3) CLEC-2 tyrosine phosphorylation is dependent on
actin polymerization; (4) tyrosine phosphorylation of CLEC-2 and downstream
signaling events are reinforced by generation of the second mediators ADP and TxA2,
which in turn activate Rac.
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regulates a number of other targets, including phosphatidylinosi-
tol 5-kinase,39 which generates the PLC2 substrate, phosphati-
dylinositol 4,5-bisphosphate. Rac also regulates actin polymer-
ization and remodeling, although the observation that ADP and
TxA2 can overcome the inhibitory effect of cytochalasin D
argues against this playing a major role downstream of Rac.
The present results report a unique series of proximal events
that underlie phosphorylation of CLEC-2 by rhodocytin and
platelet activation. Phosphorylation of CLEC-2 requires actin
polymerization and is reinforced by release of secondary
mediators and activation of Rac. This feedback pathway has
significant implications for our recent observation that the
selective inhibitor of Syk kinase, R406, abrogates phosphoryla-
tion of CLEC-2 by rhodocytin but has no effect on phosphoryla-
tion on the FcR-chain ITAM.10 Although these results are
consistent with a model in which Syk mediates phosphorylation
of the CLEC-2 hemITAM, with the role of Src kinases to
mediate activation of Syk, they could also be explained by the
loss of the feedback pathway mediated through actin polymeriza-
tion and generation of secondary mediators.
In summary, we describe a novel feedback pathway that leads to
signal amplification of the hemITAM-containing receptor CLEC-2.
This mechanism is critically dependent on actin polymerization,
secondary mediators, and Rac1 activation.
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